Structure-based Drug Design Benchmark: Do 3D Methods Really Dominate?
Not on the map. Why?
Abstract (arXiv)
Currently, the field of structure-based drug design is dominated by three main types of algorithms: search-based algorithms, deep generative models, and reinforcement learning. While existing works have typically focused on comparing models within a single algorithmic category, cross-algorithm comparisons remain scarce. In this paper, to fill the gap, we establish a benchmark to evaluate the performance of sixteen models across these different algorithmic foundations by assessing the pharmaceutical properties of the generated molecules and their docking affinities with specified target proteins. We highlight the unique advantages of each algorithmic approach and offer recommendations for the design of future SBDD models. We emphasize that 1D/2D ligand-centric drug design methods can be used in SBDD by treating the docking function as a black-box oracle, which is typically neglected. The empirical results show that 1D/2D methods achieve competitive performance compared with 3D-based methods that use the 3D structure of the target protein explicitly. Also, AutoGrow4, a 2D molecular graph-based genetic algorithm, dominates SBDD in terms of optimization ability. The relevant code is available in https://github.com/zkysfls/2024-sbdd-benchmark.
Key facts. Cited by 7 papers in the map (data through 7 Oct 2026). Builds on 17 of its 39 references that are in the map. First posted on arXiv 4 Jun 2024.
Builds on
17 of 39 references.
References · 17
- 2016Automatic chemical design using a data-driven continuous representation of moleculescited by 762
- 2015Adversarial Autoencoderscited by 359
- 2018GuacaMol: Benchmarking Models for De Novo Molecular Designcited by 294
- 2018Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Modelscited by 270
- 2017Molecular De Novo Design through Deep Reinforcement Learningcited by 264
- 2021Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Developmentcited by 258
- 2018Optimization of Molecules via Deep Reinforcement Learningcited by 199
- 2022Pocket2Mol: Efficient Molecular Sampling Based on 3D Protein Pocketscited by 182
- 2022A 3D Generative Model for Structure-Based Drug Designcited by 148
- 2022MolGenSurvey: A Systematic Survey in Machine Learning Models for Molecule Designcited by 66
- 2020Accelerating high-throughput virtual screening through molecular pool-based active learningcited by 59
- 2021Differentiable Scaffolding Tree for Molecular Optimizationcited by 53
5 more
- 2021HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Datacited by 49
- 2020MIMOSA: Multi-constraint Molecule Sampling for Molecule Optimizationcited by 48
- 2017ChemGAN challenge for drug discovery: can AI reproduce natural chemical diversity?cited by 21
- 2020Deep Molecular Dreaming: Inverse machine learning for de-novo molecular design and interpretability with surjective representationscited by 20
- 2024Uncertainty Quantification on Clinical Trial Outcome Predictioncited by 19
Built on by
Citing papers per year: 2024: 2; 2025: 3; 2026: 2.
7 papers.
- 2024D2O: Dynamic Discriminative Operations for Efficient Long-Context Inference of Large Language Modelscited by 30
- 20253DMolFormer: A Dual-channel Framework for Structure-based Drug Discoverycited by 4
- 2025Enhancing Test-Time Scaling of Large Language Models with Hierarchical Retrieval-Augmented MCTScited by 4
- 2026Beyond Affinity: A Benchmark of 1D, 2D, and 3D Methods Reveals Critical Trade-offs in Structure-Based Drug Designcited by 2
- 2026CAGenMol: Condition-Aware Diffusion Language Model for Goal-Directed Molecular Generationcited by 2
- 2024DeepProtein: Deep Learning Library and Benchmark for Protein Sequence Learningcited by 1
- 2025TransDiffSBDD: Causality-Aware Multi-Modal Structure-Based Drug Designcited by 0
- 2026CAGenMol: Condition-Aware Diffusion Language Model for Goal-Directed Molecular Generation13 Apr 2026
- 2026Beyond Affinity: A Benchmark of 1D, 2D, and 3D Methods Reveals Critical Trade-offs in Structure-Based Drug Design13 Jan 2026
- 2025Enhancing Test-Time Scaling of Large Language Models with Hierarchical Retrieval-Augmented MCTS8 Jul 2025
- 2025TransDiffSBDD: Causality-Aware Multi-Modal Structure-Based Drug Design26 Mar 2025
- 20253DMolFormer: A Dual-channel Framework for Structure-based Drug Discovery7 Feb 2025
- 2024DeepProtein: Deep Learning Library and Benchmark for Protein Sequence Learning2 Oct 2024
- 2024D2O: Dynamic Discriminative Operations for Efficient Long-Context Inference of Large Language Models18 Jun 2024